Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis

Bauss, F., Lalla, R., Endele, R., and Hothorn, L. H. The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration in ovariectomized aged rats. Osteoporos Int in press. Bjarnason, 2000, Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women, Bone, 26, 561, 10.1016/S8756-3282(00)00272-6 Boissier, 2000, Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases, Cancer Res, 60, 2949 Bonde, 1994, Immunoassay for quantifying type I collagen degradation products in urine evaluated, Clin Chem, 40, 2022, 10.1093/clinchem/40.11.2022 Christgau, 1998, Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides, Clin Chem, 44, 2290, 10.1093/clinchem/44.11.2290 Coleman, 1999, Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease, Ann Oncol, 10, 311, 10.1023/A:1008386501738 1997, Who are candidates for prevention and treatment of osteoporosis?, Osteoporos Int, 7, 1, 10.1007/BF01623453 Dooley, 1999, Ibandronate, Drugs, 57, 101, 10.2165/00003495-199957010-00011 Fleisch, 1998, Bisphosphonates, Endocr Rev, 19, 80, 10.1210/edrv.19.1.0325 Garnero, 1999, A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover, Bone, 24, 603, 10.1016/S8756-3282(99)00087-3 Genant, 1996, Noninvasive assessment of bone mineral and structure, J Bone Miner Res, 11, 707, 10.1002/jbmr.5650110602 Heaney, 1997, Bisphosphonate effects and the bone remodeling transient, J Bone Miner Res, 12, 1143, 10.1359/jbmr.1997.12.8.1143 Kline, 1992, Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection, J Chromatogr, 583, 183, 10.1016/0378-4347(92)80551-Z Mitchell, 2000, Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers, J Clin Pharmacol, 40, 258, 10.1177/00912700022008928 Neugebauer, 1998, Pharmacokinetics of ibandronate, a highly potent antiresorptive drug on bone metabolism in patients with multiple myeloma, Eur J Clin Pharmacol, 54, 18 Pecherstorfer, 1996, Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy, J Clin Oncol, 14, 268, 10.1200/JCO.1996.14.1.268 Ravn, 1999, Alendronate and estrogen-progestin in the long-term prevention of bone loss, Ann Intern Med, 131, 935, 10.7326/0003-4819-131-12-199912210-00005 Ravn, 1998, Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment, Bone, 22, 559, 10.1016/S8756-3282(98)00044-1 Ravn, 1999, Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group, Bone, 24, 237, 10.1016/S8756-3282(98)00183-5 Ravn, 1996, The effect on bone mass and bone markers of different doses of ibandronate, Bone, 19, 527, 10.1016/S8756-3282(96)00229-3 Ravn, 1999, Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the Early Postmenopausal Intervention Cohort Study, J Clin Endocrinol Metab, 84, 2363 Rizzoli, 1999, Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy, J Clin Endocrinol Metab, 84, 3545, 10.1210/jcem.84.10.6026 Rosenquist, 1998, Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen, Clin Chem, 44, 2281, 10.1093/clinchem/44.11.2281 Rosenquist, 1995, Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies, Clin Chem, 41, 1439, 10.1093/clinchem/41.10.1439 Thiebaud, 1997, Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis, Am J Med, 103, 298, 10.1016/S0002-9343(97)00249-0 Tonino, 2000, Skeletal benefits of alendronate, J Clin Endocrinol Metab, 85, 3109 Woitge, 2000, Short- and long-term effects of ibandronate treatment on bone turnover in Paget’s disease of bone, Clin Chem, 46, 684, 10.1093/clinchem/46.5.684